The FDA has announced that a specific lot of extended-release Xanax, one of the most commonly used medications for anxiety and panic disorders, has been recalled by Viatris Specialty. The issue arose when the tablets did not break down at the expected rate, potentially reducing their effectiveness or increasing side effects. The recall has been classified as a Class II event, meaning exposure to the product may cause temporary or medically reversible adverse health consequences while the likelihood of serious harm remains low. The affected medication includes 3-milligram Xanax XR tablets sold in bottles of 60. The California Board of Pharmacy has urged pharmacies to review their quality assurance and recall policies and procedures.